Portola Pharmaceuticals to Announce Third Quarter 2013 Financial Results and Host Conference Call on Tuesday, November 5, 201...
31 Octobre 2013 - 1:00PM
Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it
will host a webcast and conference call to discuss the Company's
financial results for the quarter ended September 30, 2013 and to
provide a general business overview on Tuesday, November 5, 2013 at
4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Conference Call Details
To access the live conference call, please dial (866) 515-2912
from the U.S. and Canada, or +1(617) 399-5126 internationally, and
use the passcode 80397477. Please dial in 10 minutes prior to the
start of the call.
To access the live and subsequently archived webcast of the
conference call, go to the Investor Relations section of the
company's website at http://investors.portola.com. Please connect
to the website at least 15 minutes prior to the call to allow for
any software download that may be necessary. A replay of the
webcast will be available on the Company's website for 30 days
following the live event.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company focused
on the development and commercialization of novel therapeutics in
the areas of thrombosis, other hematologic disorders and
inflammation. Portola's wholly-owned lead compound, betrixaban, is
a novel, oral, once-daily Factor Xa inhibitor in Phase 3
development for extended-duration prophylaxis of a form of
thrombosis known as venous thromboembolism (VTE) in acute medically
ill patients. Currently, there is no anticoagulant approved for
extended-duration VTE prophylaxis in this population. Portola's
second lead development candidate, andexanet alfa (PRT4445*), has
the potential to be the first universal antidote to reverse the
effects of Factor Xa inhibitors in patients who suffer an
uncontrolled bleeding episode or who require emergency surgery.
Portola retains full, worldwide commercial rights to andexanet
alfa. Portola's third product candidate, PRT2070, is an orally
available kinase inhibitor that uniquely inhibits two validated
tumor proliferation pathways -- spleen tyrosine kinase (Syk) and
janus kinase (JAK). It is currently being studied in patients with
genetically-defined hematologic cancers, as well as for patients
who have failed therapy due to relapse or acquired mutations.
Portola's fourth program is partnered with Biogen Idec and is
focused on the development of PRT2607, a selective Syk inhibitor.
For more information, visit www.portola.com.
*PRT4445 has a proposed International Nonproprietary Name (pINN)
of andexanet alfa.
CONTACT: Investor Contact:
Alexandra Santos
Portola Pharmaceuticals
ir@portola.com
650.246.7239
Media Contact:
Joey Fleury
BrewLife
jfleury@brewlife.com
415.946.1090
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur